Your session is about to expire
← Back to Search
Study Summary
This trial will study the effect of 3 drugs on vesatolimod, a drug used to treat HIV. The study will also evaluate the safety of this combination of drugs.
- HIV
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 162 Patients • NCT02166047Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had a high fever within the last 35 days before the start of the study.You have a serious heart condition or a family history of a certain heart syndrome that can cause abnormal heart rhythms.You are allergic to the study drugs or any ingredients in them.You have a medical condition where your immune system mistakenly attacks your own body.You have a serious skin condition like a rash, eczema, psoriasis, or hives.You are taking a specific combination of medications that include BIC, DTG, RAL, or DOR, along with Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Examples of acceptable combinations include BIC/emtricitabine/tenofovir, DTG/ABC/3TC, DTG/3TC, DTG + emtricitabine/tenofovir, or DOR/3TC/tenofovir.To make the criterion more understandable, I need the specific conditions or events that should be mentioned in the criterion. Could you please provide the list of conditions or events that should be included?You have a strong sensitivity or allergy to certain medications that can cause severe reactions.You have experienced fainting, rapid or irregular heartbeats, or unexplained dizziness.You have a severe stomach ulcer that needs ongoing treatment for at least 6 months.
- Group 1: Vesatolimod (VES) + Cobicistat (COBI) + Voriconazole (VOR)
- Group 2: Vesatolimod (VES) + Rifabutin (RFB)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals able to enroll in this experiment currently?
"Indeed, according to clinicaltrials.gov records this study is actively recruiting participants after the original posting on August 19th 2022 and recent edits made on November 30th 2022. 45 candidates are being sought from 5 different medical facilities."
How many volunteers have joined the study thus far?
"This research requires 45 eligible patients to join the study from select sites such as Collaborative Neuroscience Research, LLC. in Long Beach and Advanced Pharma, CR, LLC. located in Miami."
What can be said about the safety profile of Vesatolimod for human consumption?
"The evidence available to back up Vesatolimod's safety and efficacy is limited, so it received a rating of 1 on our scale."
Are there multiple venues conducting this clinical experiment in the urban area?
"This trial has 5 participating clinical sites, including Collaborative Neuroscience Research, LLC. in Long Beach, Advanced Pharma, CR, LLC. in Miami and Clinical Pharmacology of Miami, LLC. located West Palm Beach; amongst other recruitment centres."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger